|
Trading Halt
|
29 June 2023 at 9:55am
|
|
Emyria Receives Ethics Approval for MDMA-assisted Therapy
|
8 June 2023 at 9:35am
|
|
Section 708A(5)(e) Notice
|
10 May 2023 at 7:05pm
|
|
Application for quotation of securities - EMD
|
10 May 2023 at 6:50pm
|
|
Notification regarding unquoted securities - EMD
|
10 May 2023 at 6:45pm
|
|
Proposed issue of securities - EMD
|
1 May 2023 at 10:35am
|
|
Emyria Completes $2.5m Placement
|
1 May 2023 at 10:35am
|
|
March 2023 Quarterly Activities Report and Appendix 4C
|
28 April 2023 at 2:55pm
|
|
Trading Halt
|
27 April 2023 at 9:50am
|
|
Emyria Unveils Highest Potency CBD Capsule for FDA Pathway
|
24 April 2023 at 9:55am
|
|
Emyria to Develop Psilocybin Therapy Care Model
|
18 April 2023 at 8:40am
|
|
Emyria, Aspen Sign Binding Commercial Term Sheet for EMD-RX5
|
4 April 2023 at 9:15am
|
|
Strong Recruitment for EMD-RX5 Phase 3 Trial
|
23 March 2023 at 8:40am
|
|
Emyria Grows MDMA Asset for Neuro & Mental Health Therapy
|
20 March 2023 at 8:35am
|
|
Broker Briefing Presentation
|
16 March 2023 at 8:35am
|
|
Broker Briefing Biotech & Nutrition Investor Webinar
|
15 March 2023 at 11:05am
|
|
Emyria partners with PAX Centre for MDMA-assisted therapy
|
7 March 2023 at 8:40am
|
|
Company Secretary Change
|
1 March 2023 at 10:10am
|
|
Notice under section 708A(5)(e) of the Corporations Act
|
27 February 2023 at 8:25am
|
|
Half Yearly Report and Accounts
|
27 February 2023 at 8:25am
|
|
Investor Presentation
|
24 February 2023 at 12:59pm
|
|
Change of Director's Interest Notice x 5
|
23 February 2023 at 5:35pm
|
|
Notification regarding unquoted securities - EMD
|
23 February 2023 at 5:35pm
|
|
Application for quotation of securities - EMD
|
23 February 2023 at 5:25pm
|
|
Emyria secures clinical-grade MDMA supply for Aust patients
|
13 February 2023 at 9:55am
|
|
Emyria expands MDMA programs following landmark TGA decision
|
6 February 2023 at 9:50am
|
|
Appendix 4C - Quarterly
|
31 January 2023 at 9:55am
|
|
Change in substantial holding SW
|
31 January 2023 at 9:45am
|
|
First dosing commenced for pivotal EMD-RX5 Phase 3 trial
|
30 January 2023 at 10:00am
|
|
Results of Meeting
|
25 January 2023 at 6:30pm
|
|
Emyria receives $2.1M R&D tax incentive refund
|
12 January 2023 at 10:05am
|
|
Biotech Showcase San Francisco Presentation
|
10 January 2023 at 9:50am
|
|
Notification of cessation of securities - EMD
|
5 January 2023 at 10:10am
|
|
Letter to Shareholders/Notice of General Meeting/Proxy Form
|
16 December 2022 at 1:35pm
|
|
Notice under section 708A(5)(e) of the Corporations Act
|
7 December 2022 at 6:50pm
|
|
Application for quotation of securities - EMD
|
7 December 2022 at 6:45pm
|
|
Upcoming Emyria CEO Webinars
|
7 December 2022 at 9:40am
|
|
Emyria accepted into National Institutes of Health Program
|
28 November 2022 at 9:30am
|
|
Change of Director's Interest Notice
|
28 November 2022 at 8:40am
|
|
Notification regarding unquoted securities - EMD
|
25 November 2022 at 12:40pm
|
|
Notification regarding unquoted securities - EMD
|
25 November 2022 at 12:30pm
|
|
Placement completion and secondary trading notice
|
23 November 2022 at 10:30am
|
|
Investor Presentation
|
23 November 2022 at 10:20am
|
|
Notification regarding unquoted securities - EMD
|
23 November 2022 at 10:05am
|
|
Application for quotation of securities - EMD
|
23 November 2022 at 9:55am
|
|
Notification of cessation of securities - EMD
|
18 November 2022 at 7:20pm
|
|
Amended Constitution
|
17 November 2022 at 11:00am
|
|
Appendix 4C - Quarterly
|
31 October 2022 at 3:15pm
|
|
Proposed issue of securities - EMD
|
31 October 2022 at 10:40am
|
|
Proposed issue of securities - EMD
|
31 October 2022 at 10:40am
|
Emyria